Inside Sionna’s Bid To Normalize CFTR Function
Failed to add items
Add to cart failed.
Add to wishlist failed.
Remove from wishlist failed.
Follow podcast failed
Unfollow podcast failed
Inside Sionna’s Bid To Normalize CFTR Function
-
Narrated by:
-
Written by:
About this listen
Send us a text
Two leaders from Sionna Therapeutics walk through a 15‑year journey from Genzyme science to a public company advancing NBD1‑targeted therapies in cystic fibrosis. We examine why most patients still fall short of normal CFTR, how a predictive assay de‑risks choices, and what it takes to finance, hire, and execute with patients as the North Star.
Visit: sionnatx.com
Transformation in Trials is a podcast investigating how we can change life sciences to get treatment to patients faster.
Getting treatment to patients faster requires well-functioning organizations. How do we do that? Ivanna Rosendal has written a book called Maneuvering Monday, about how a group of people try to make their organization better. You are certain to have a good laugh at their expense. And potentially get inspired how you can help make your company better.
I have been independently producing this episode since 2021. You can now support the show by Buying Us a Coffee. Each episode costs 99USD/ 85 EUR to produce.
Join the show as a guest - apply via this Form.
Support the show
________
Reach out to Ivanna Rosendal
Join the conversation on our LinkedIn page